Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (171-180 of 349) with videos related to

Pageof 35
Sort By:
BJU International|July 14, 2012
Impact of surgical margin status on prostate-cancer-specific mortalityHeather J Chalfin, Michael Dinizo, Bruce J Trock, et al.
BJU International|July 2, 2010
The impact of preoperative erectile dysfunction on survival after radical prostatectomyMisop Han, Bruce J Trock, Alan W Partin, et al.
Reviews in Urology|March 26, 2013
Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GAJ Curtis Nickel, Alan W Partin, Jayabalan Nirmal, et al.
Urology|February 29, 2008
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomyDavid J Hernandez, Matthew E Nielsen, Misop Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortalityStephen J Freedland, Elizabeth B Humphreys, Leslie A Mangold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Small integrin-binding proteins as serum markers for prostate cancer detectionAlka Jain, Dianalee A McKnight, Larry W Fisher, et al.
The Journal of Urology|July 4, 2006
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/mlDanil V Makarov, Elizabeth B Humphreys, Leslie A Mangold, et al.
International Journal of Cancer|November 13, 2008
Endoglin (CD105) as a urinary and serum marker of prostate cancerKazutoshi Fujita, Charles M Ewing, David Y S Chan, et al.
World Journal of Urology|September 15, 2020
A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid useMitchell M Huang, Hiten D Patel, Zhuo T Su, et al.
The Journal of Urology|August 13, 2003
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/mlMasood A Khan, Alan W Partin, Harry G Rittenhouse, et al.
Pageof 35

Showing results (171-180 of 349) with videos related to

Sort By:
Pageof 35
BJU International|July 14, 2012
Impact of surgical margin status on prostate-cancer-specific mortalityHeather J Chalfin, Michael Dinizo, Bruce J Trock, et al.
BJU International|July 2, 2010
The impact of preoperative erectile dysfunction on survival after radical prostatectomyMisop Han, Bruce J Trock, Alan W Partin, et al.
Reviews in Urology|March 26, 2013
Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GAJ Curtis Nickel, Alan W Partin, Jayabalan Nirmal, et al.
Urology|February 29, 2008
Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomyDavid J Hernandez, Matthew E Nielsen, Misop Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortalityStephen J Freedland, Elizabeth B Humphreys, Leslie A Mangold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Small integrin-binding proteins as serum markers for prostate cancer detectionAlka Jain, Dianalee A McKnight, Larry W Fisher, et al.
The Journal of Urology|July 4, 2006
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/mlDanil V Makarov, Elizabeth B Humphreys, Leslie A Mangold, et al.
International Journal of Cancer|November 13, 2008
Endoglin (CD105) as a urinary and serum marker of prostate cancerKazutoshi Fujita, Charles M Ewing, David Y S Chan, et al.
World Journal of Urology|September 15, 2020
A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid useMitchell M Huang, Hiten D Patel, Zhuo T Su, et al.
The Journal of Urology|August 13, 2003
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/mlMasood A Khan, Alan W Partin, Harry G Rittenhouse, et al.
Pageof 35